Department of Surgical, Gastroenterological and Oncological Sciences (DiSCOG), Clinica Chirurgica I, University of Padua, Padua, Italy.
Department of Radiation Oncology, Centro di Riferimento Oncologico, National Cancer Institute, Aviano, Italy.
Tech Coloproctol. 2017 Aug;21(8):633-640. doi: 10.1007/s10151-017-1665-1. Epub 2017 Jul 28.
Rectum-sparing approaches appear to be appropriate in rectal cancer patients with a major (mCR) or complete clinical response (cCR) after neoadjuvant therapy. The aim of the present study is to evaluate the effectiveness of rectum-sparing approaches at 2 years after the completion of neoadjuvant treatment.
Patients with rectal adenocarcinoma eligible to receive neoadjuvant therapy will be prospectively enrolled. Patients will be restaged 7-8 weeks after the completion of neoadjuvant therapy and those with mCR (defined as absence of mass, small mucosal irregularity no more than 2 cm in diameter at endoscopy and no metastatic nodes at MRI) or cCR will be enrolled in the trial. Patients with mCR will undergo local excision, while patients with cCR will either undergo local excision or watch and wait policy. The main end point of the study is to determine the percentage of rectum preservation at 2 years in the enrolled patients.
This protocol is the first prospective trial that investigates the role of both local excision and watch and wait approaches in patients treated with neoadjuvant therapy for rectal cancer. The trial is registered at clinicaltrials.gov (NCT02710812).
新辅助治疗后,直肠肿瘤患者出现主要(mCR)或完全临床缓解(cCR)时,采用保肛方法似乎是合适的。本研究的目的是评估新辅助治疗完成后 2 年保肛方法的有效性。
将前瞻性招募有资格接受新辅助治疗的直肠腺癌患者。新辅助治疗完成后 7-8 周对患者进行重新分期,对 mCR(定义为内镜下无肿块,粘膜小不规则,直径不超过 2cm,且 MRI 无转移淋巴结)或 cCR 患者入组试验。mCR 患者行局部切除,而 cCR 患者则行局部切除或观察等待策略。本研究的主要终点是确定入组患者 2 年内保肛率。
该方案是首个前瞻性研究,旨在探讨新辅助治疗直肠癌患者局部切除和观察等待策略的作用。该试验在 clinicaltrials.gov 注册(NCT02710812)。